MedTrace Logo

Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response

NCT01610362 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-04-09

No results posted yet for this study

Summary

Dosage of rabies immune globulin was calculated from the victim's body weight, then the amount of rabies immune globulin would be injected as much as possible to all of the wounds. Increase dosage of rabies immune globulin was needed in situation of multiple severe bite-wounds especially among children whose had lower body weight than adults. Our study would be conducted in order to determine whether the increase dosage of rabies immune globulin would interfere with the protective antibody levels against rabies.

Conditions

  • Rabies

Interventions

BIOLOGICAL

Human Rabies Immune Globulin

HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0

Sponsors & Collaborators

  • Queen Saovabha Memorial Institute

    lead OTHER

Principal Investigators

  • Suda Sibunruang, M.D. · Queen Saovabha Memorial Institute, Thai Red Cross Society

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01610362 on ClinicalTrials.gov